Masitinib

From Wikipedia, the free encyclopedia - View original article

Masitinib.svg
Systematic (IUPAC) name
4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide
Clinical data
Trade namesMasivet, Kinavet
AHFS/Drugs.comInternational Drug Names
Legal status ?
Identifiers
CAS number790299-79-5
ATC codeL01XE22
PubChemCID 10074640
ChemSpider8250179
Chemical data
FormulaC28H30N6OS 
Mol. mass498.64 g/mol
 
Jump to: navigation, search
Masitinib.svg
Systematic (IUPAC) name
4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide
Clinical data
Trade namesMasivet, Kinavet
AHFS/Drugs.comInternational Drug Names
Legal status ?
Identifiers
CAS number790299-79-5
ATC codeL01XE22
PubChemCID 10074640
ChemSpider8250179
Chemical data
FormulaC28H30N6OS 
Mol. mass498.64 g/mol

Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs.[1][2] Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.

Masitinib is being studied for several human conditions including cancers. It is used in Europe to fight orphan diseases.[3]

Mechanism of action[edit]

Masitinib inhibits the receptor tyrosine kinase c-Kit which is displayed by various types of tumour.[2] It also inhibits the platelet derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR).[citation needed]

References[edit]

  1. ^ Hahn, K.A.; Oglivie, G.; Rusk, T.; Devauchelle, P.; Leblanc, A.; Legendre, A.; Powers, B.; Leventhal, P.S.; Kinet, J.-P.; Palmerini, F.; Dubreuil, P.; Moussy, A.; Hermine, O. (2008). "Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors". Journal of Veterinary Internal Medicine 22 (6): 1301–1309. doi:10.1111/j.1939-1676.2008.0190.x. ISSN 0891-6640. 
  2. ^ a b Information about Masivet at the European pharmacy agency website
  3. ^ Orphan designation for Masitinib at the European pharmacy agency website